Literature DB >> 15378078

Mechanisms controlling pathogenesis and survival of leukemic stem cells.

Craig T Jordan1, Monica L Guzman.   

Abstract

Stem cells are an integral component of normal mammalian physiology and have been intensively studied in many systems. Intriguingly, substantial evidence indicates that stem cells also play an important role in the initiation and pathogenesis of at least some cancers. In particular, myeloid leukemias have been extensively characterized with regard to stem and progenitor cell involvement. Thus, as a focal point for both scientific and therapeutic endeavors, leukemic stem cells (LSC) represent a critical area of investigation. LSC appear to retain many characteristics of normal hematopoietic stem cells (HSC) as evidenced by a hierarchical developmental pattern, a mostly quiescent cell cycle profile, and an immunophenotype very similar to HSC. Consequently, defining unique properties of LSC remains a high priority in order to elucidate the molecular mechanisms driving stem cell transformation, and for developing therapeutic strategies that specifically target the LSC population. In this review, we discuss emerging concepts in the field and describe how various molecular and cellular characteristics of leukemia cells might be exploited as a means to preferentially ablate malignant stem cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378078     DOI: 10.1038/sj.onc.1207935

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  Novel agents inhibit human leukemic cells.

Authors:  Wei-ping Yu; Juan Li
Journal:  Acta Pharmacol Sin       Date:  2012-01-09       Impact factor: 6.150

Review 2.  Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.

Authors:  Roland B Walter; Frederick R Appelbaum; Elihu H Estey; Irwin D Bernstein
Journal:  Blood       Date:  2012-01-27       Impact factor: 22.113

Review 3.  GPCRs in stem cell function.

Authors:  Van A Doze; Dianne M Perez
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

4.  p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.

Authors:  Zhen Zhao; Johannes Zuber; Ernesto Diaz-Flores; Laura Lintault; Scott C Kogan; Kevin Shannon; Scott W Lowe
Journal:  Genes Dev       Date:  2010-07-01       Impact factor: 11.361

5.  Targeting leukemia stem cells: The new goal of therapy in adult acute myeloid leukemia.

Authors:  Xavier Thomas
Journal:  World J Stem Cells       Date:  2009-12-31       Impact factor: 5.326

Review 6.  FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Authors:  Zainab Jagani; Amrik Singh; Roya Khosravi-Far
Journal:  Biochim Biophys Acta       Date:  2007-10-16

Review 7.  Identification and targeting of cancer stem cells.

Authors:  Tobias Schatton; Natasha Y Frank; Markus H Frank
Journal:  Bioessays       Date:  2009-10       Impact factor: 4.345

8.  An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells.

Authors:  Monica L Guzman; Randall M Rossi; Sundar Neelakantan; Xiaojie Li; Cheryl A Corbett; Duane C Hassane; Michael W Becker; John M Bennett; Edmund Sullivan; Joshua L Lachowicz; Andrew Vaughan; Christopher J Sweeney; William Matthews; Martin Carroll; Jane L Liesveld; Peter A Crooks; Craig T Jordan
Journal:  Blood       Date:  2007-09-05       Impact factor: 22.113

9.  Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance.

Authors:  Jiangbing Zhou; Julia Wulfkuhle; Hao Zhang; Peihua Gu; Yanqin Yang; Jianghong Deng; Joseph B Margolick; Lance A Liotta; Emanuel Petricoin; Ying Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

Review 10.  The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior.

Authors:  Yan Liu; Shannon E Elf; Takashi Asai; Yasuhiko Miyata; Yuhui Liu; Goro Sashida; Gang Huang; Silvana Di Giandomenico; Andrew Koff; Stephen D Nimer
Journal:  Cell Cycle       Date:  2009-10-01       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.